Final Results - Part 3 of 3

AstraZeneca PLC
31 January 2008

AstraZeneca Development Pipeline

31 January 2008


Line Extensions

     Compound                Mechanism          Area Under Investigation   Phase       Estimated Filing
                                                                                       MAA            NDA

Cardiovascular

Atacand             angiotensin II antagonist   diabetic retinopathy        III       1H 2009        1H 2009

Atacand Plus        angiotensin II antagonist/  32/12.5 mg, 32/25 mg for    III       2Q 2008
                    thiazide diuretic           hypertension
Crestor             statin                      atherosclerosis             III       Launched       Launched

Crestor             statin                      outcomes End Stage Renal    III       1H 2009        1H 2009
                                                Disease
Crestor             statin                      outcomes in subjects        III         2010           2010
                                                with elevated CRP
Saxagliptin/        DPP-4 + biguanide FDC       diabetes                    III
Metformin FDC

Dapagliflozin/      SGLT2 + biguanide FDC       diabetes                    III
Metformin FDC

Gastrointestinal

Nexium              proton pump inhibitor       peptic ulcer bleeding       III       2Q 2008        2Q 2008

Nexium Sachet       proton pump inhibitor       GERD                        III      Approved**      Launched
formulation

Nexium              proton pump inhibitor       extra-oesophageal reflux    II        2H 2009*       2H 2009*
                                                disease
Nexium low dose     proton pump inhibitor       low dose aspirin            III                      1H 2009
aspirin combination                             associated peptic ulcer

Neuroscience

Seroquel XR         D2/5HT2 antagonist          schizophrenia               III       Approved       Launched

Seroquel            D2/5HT2 antagonist          bipolar maintenance         III       2Q 2008         Filed

Seroquel            D2/5HT2 antagonist          bipolar depression          III       1Q 2008        Launched

Seroquel XR         D2/5HT2 antagonist          generalised anxiety         III       4Q 2008        2Q 2008
                                                disorder
Seroquel XR         D2/5HT2 antagonist          major depressive            III       3Q 2008        1Q 2008
                                                disorder
Seroquel XR         D2/5HT2 antagonist          bipolar mania               III       1Q 2008         Filed

Seroquel XR         D2/5HT2 antagonist          bipolar depression          III       1Q 2008         Filed

Oncology & Infection

Faslodex            oestrogen receptor          1st line advanced breast    III
                    antagonist                  cancer

Faslodex            oestrogen receptor          adjuvant                    III
                    antagonist

Iressa              EGFR-TK inhibitor           NSCLC                       III       2Q 2008

FluMist             live, attenuated,           influenza                   III       2Q 2008        Launched
(MedImmune)         intranasal influenza virus
                    vaccine



*Project Extraesophageal reflux disease (reflux asthma) will be completed but
 will not result in a regulatory filing.


** Approved by EU RMS, Mutual Recognition Procedure ongoing


Line Extensions (continued)

     Compound                Mechanism          Area Under Investigation    Phase   Estimated Filing
                                                                                    MAA          NDA

Respiratory & Inflammation

Symbicort pMDI      inhaled steroid/fast onset, asthma                       III       Filed*      Launched**
                    long-acting beta2
                    agonist

Symbicort pMDI      inhaled steroid/fast onset, COPD                         III       Filed*        2Q 2008
                    long-acting beta2
                    agonist



*To be supplemented in 2008 with data supporting two additional strengths.

**US approval based on 12 years and above.


NCE's



Phase III


     Compound                Mechanism          Area Under Investigation   Phase      Estimated Filing
                                                                                      MAA            NDA

Cardiovascular

AZD6140             ADP receptor antagonist     arterial thrombosis         III       2H 2009        2H 2009

Saxagliptin         dipeptidyl peptidase-4      diabetes                    III       2H 2009        2Q 2008
                    (DPP-4) inhibitor

Dapagliflozin       sodium-glucose              diabetes                    III         2010           2010
                    cotransporter-2 (SGLT2)
                    inhibitor

Crestor/ABT-335     statin + fibrate fixed      dyslipidaemia               III                      2H 2009
                    combination
Neuroscience

PN400               naproxen +esomeprazole      signs and symptoms of OA    III       1H 2009        1H 2009
                                                , RA, and AS
Oncology & Infection

Zactima             VEGF/EGF TK inhibitor with  NSCLC                       III       4Q 2008        4Q 2008
                    RET kinase activity

Recentin            VEGF signalling inhibitor   NSCLC and CRC             II/III        2010           2010
                    (VEGFR-TKI)

Recentin            VEGF signalling inhibitor   recurrent glioblastoma      III         2010           2010
                    (VEGFR-TKI)

ZD4054              endothelin A receptor       hormone resistant           III         2011           2011
                    antagonist                  prostate cancer

Motavizumab         humanized monoclonal        RSV prevention              III       1H 2009        1Q 2008
(MedImmune)         antibody




NCE's



Phases I and II

     Compound                Mechanism          Area Under Investigation   Phase       Estimated Filing
                                                                                       MAA            NDA

Cardiovascular

AZD0837             thrombin inhibitor          thrombosis                  II          2012           2012

AZD4121             cholesterol absorption      dyslipidaemia               II
                    inhibitor

AZD2207             CB1 antagonist              diabetes/obesity            II

AZD1175             CB1 antagonist              diabetes/obesity             I

AZD1305             antiarrhythmic              arrhythmias                  I

AZD6370             GLK activator               diabetes                     I

Gastrointestinal

AZD3355             inhibitor of transient      GERD                        II          2011           2011
                    lower oesophageal sphincter
                    relaxations (TLESR)

AZD2066             metabotropic Glutamate      GERD                         I
                    receptors subtype 5

AZD1386             Vanilloid receptor 1        GERD                         I
                    antagonist
Neuroscience

AZD3480             neuronal nicotinic receptor cognitive disorders in      II          2011           2011
                    agonist                     schizophrenia

AZD3480             neuronal nicotinic receptor Alzheimers                  II          2011           2011
                    agonist

AZD6765             NMDA receptor antagonist    depression                  II


AZD2327             enkephalinergic receptor    anxiety and depression       I
                    modulator

AZD5904             inhibitor of                multiple sclerosis           I
                    myeloperoxidase (MPO)

AZD3241             inhibitor of                Parkinson's disease          I
                    myeloperoxidase (MPO)

AZD0328             selective neuronal          Alzheimers                   I
                    nicotinic receptor agonist

AZD1940             CB receptor agonist         nociceptive and              I
                                                neuropathic pain

AZD2624             NK receptor antagonist      schizophrenia                I


AZD1386             Vanilloid receptor          chronic nociceptive pain     I
                    antagonist

AZD2066             metabotropic Glutamate      chronic nociceptive pain     I
                    receptors

AZD7325             GABA receptor subtype       anxiety                      I
                    partial agonist

AZD6280             GABA receptor subtype       anxiety                      I
                    partial agonist

TC-5619 (Targacept) neuronal nicotinic receptor cognitive disorders in       I
                    agonist                     schizophrenia



Phases I and II (continued)


     Compound                Mechanism          Area Under Investigation   Phase       Estimated Filing
                                                                                        MAA            NDA

Oncology & Infection

Zactima             VEGF/EGF TK inhibitor with  medullary thyroid cancer    II        4Q 2008        4Q 2008
                    RET kinase activity

CytoFab             anti-TNF-alpha polyclonal   severe sepsis               II
                    antibody

AZD6244             MEK inhibitor               solid tumours               II
(ARRY-142886)

AZD2281             PARP inhibitor              breast cancer               II

EBV vaccine*        Epstein-Barr Virus Vaccine  post-transplant             II
                                                proliferative disease

AZD2836             5a replicon                 hepatitis C                 II

AZD0530             SRC kinase inhibitor        solid tumours and           II
                                                haematological
                                                malignancies

MEDI-524            MAb targets F-Protein       early and late treatment    II
(Motavizumab)                                   of disease in paeds >1
                                                yr


MEDI-561            HSP 90 inhibitor            solid tumours               II                         2010


AZD1152             aurora kinase inhibitor     solid tumours and            I
                                                haematological
                                                malignancies

AZD4769             EGFR tyrosine kinase        solid tumours                I
                    inhibitor

AZD4877             Cell Cycle Agent            solid tumours and            I
                                                haematological
                                                malignancies

AZD8931             erbB kinase inhibitor       solid tumours                I

AZD7762             CHK1 Kinase Inhibitor       solid tumours                I

AZD8330             MEK inhibitor               solid tumours                I
(ARRY-424704)

CAT-8015            recombinant immunotoxin     haematological               I
                                                malignancies
MEDI-534            RSV/PIV-3 vaccine           intranasal immunisation      I


MEDI-560            PIV-3 vaccine               intranasal immunisation      I


H5N1                H5N1 Influenza Virus        pandemic influenza           I
                    Vaccine                     vaccine

MEDI-538            CD19 B cells                leukaemia/lymphoma           I


MEDI-564            F protein inhibitor         RSV treatment                I


CMV Vaccine         CMV vaccine                 cytomegalovirus              I

MEDI-557            YTE - extended half-life    RSV Prophylaxis              I
                    RSV Mab



*Partnered product


Phases I and II (continued)

     Compound                Mechanism          Area Under Investigation   Phase        Estimated Filing
                                                                                        MAA            NDA

Respiratory & Inflammation

AZD9056             ion channel blocker (P2X7)  rheumatoid arthritis        II          2012           2012

AZD1981             Prostaglandin receptor      asthma                      II
                    antagonist

AZD5672             Chemokine antagonist (CCR5) rheumatoid arthritis        II          2012           2012

MEDI-528            anti-IL-9 antibody          asthma                      II

AZD4818             CCR1 antagonist             COPD                         I

CAT-354             anti-IL-13 antibody         asthma                       I

AZD5904             MPO inhibitor               COPD                         I

AZD1744             Dual CCR3/H1 receptor       COPD                         I
                    antagonist

AZD1236             Matrix metalloproteinase    COPD                         I
                    inhibition

AZD9668             Neutrophil Elastase         COPD                         I
                    Inhibitor

MEDI-563            anti-IL-5R antibody         asthma                       I


MEDI-545            anti-IFNa antibody          SLE, myositis                I

Pneumococcal        Pneumococcal vaccine        Streptococcus pneumoniae     I
vaccine*

AZD3199             iLABA                       asthma/COPD                  I

CAM-3001            anti-GM-CSFR antibody       rheumatoid arthritis         I



*Partnered product

AstraZeneca Development Pipeline

Discontinued Projects vs 26 July 2007 HY


Cardiovascular & Gastrointestinal

NCE/Line Extension                    Compound                         Area Under Investigation

NCE                                   AZD1283                               thrombosis
NCE                                   AZD3988                               diabetes/obesity
NCE                                   AZD3118                               arrhythmias
LE                                    Crestor Outcomes CHF                  CHF
LE                                    Nexium NSAID GI  US                   ulcer healing
LE                                    Nexium NSAID GI side effects US       symptom resolution
NCE                                   AZD9056                               Inflammatory bowel disease


Neuroscience

NCE/Line Extension                   Compound                           Area Under Investigation

NCE                                   AZD3783                               anxiety & depression
NCE                                   AZD1080                               Alzheimers


Oncology & Infection

NCE/Line Extension                    Compound                          Area Under Investigation

NCE                                   AZD6495                               range of tumours
NCE                                   CAT-5001                              solid tumours
NCE                                   AZD5180                               solid tumours
NCE                                   hMPV MAb                              respiratory infection
NCE                                   MEDI-552                              leukaemia/lymphoma
NCE                                   MEDI-555                              solid tumours
NCE                                   MEDI-562                              solid tumours
NCE                                   CAT-3888                              hairy cell leukaemia
NCE                                   AZD9935                               solid tumours
NCE                                   AZD4992                               breast cancer



Respiratory & Inflammation

NCE/Line Extension                    Compound                          Area Under Investigation

NCE                                   MEDI-552                              inflammation
NCE                                   Anti-IL6 MAb                          inflammation
NCE                                   anti Chitinase MAb                    asthma/COPD
NCE                                   AZD6357                               osteoarthritis
NCE                                   AZD6605                               osteoarthritis



Comments

As disclosure of compound information is balanced by the business need to
maintain confidentiality, information in relation to some compounds listed here
has not been disclosed at this time.



Compounds in development are displayed by phase.



Projects shaded in grey were communicated as discontinued at the Biologics
Review, Dec 7th 2007



Abbreviations:



MAA - Marketing Authorisation Application (Europe).

NDA - New Drug Application/Biologics Licensing Application (USA).




                      This information is provided by RNS
            The company news service from the London Stock Exchange